Rafael Torre
Clinical Psychopharmacologist
Data updated
Research Footprint
Rafael Torre appears in 8 tracked papers (2006–2023), most studied alongside MDMA, 2C-X and Ayahuasca, across Healthy Volunteers, Depressive Disorders and Medicinal Chemistry & Drug Development.
Most-cited paper: Pharmacology of MDMA in humans (178 citations).
Frequent co-authors: Rafael De La Torre, Magí Farré and Johannes Ramaekers.
Background & Research
Rafael de la Torre is a clinical psychopharmacologist whose work focuses on the human pharmacology and subjective effects of entactogens and substituted stimulants. His publications and trial involvement include observational and experimental studies of 2C‑B, comparative human pharmacology of mephedrone versus MDMA, and mechanistic investigations of MDMA’s acute psychological effects. He has contributed to bridging controlled human psychopharmacology with psychometric, genetic and receptor‑mechanism approaches.
De la Torre’s research has addressed both population‑level effects (for example, mood changes in polydrug ecstasy users) and receptor and genotype moderators of drug response — notably studies implicating the 5‑HT2A receptor in specific MDMA‑induced changes in emotional processing, and work examining how serotonin transporter genotype (l‑allele homozygosity) relates to MDMA’s effects on depressive mood ratings in female users. Methodologically, his contributions span observational human studies, controlled pharmacological challenge designs, psychometric assessment and incorporation of genetic and receptor‑blockade probes to parse mechanisms underlying subjective and affective drug effects.
Key Impact
Notable for experimental human pharmacology studies elucidating the subjective and receptor-mediated effects of entactogens and related stimulants such as MDMA, 2C‑B and mephedrone.
Collaboration Network
17 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Rafael Torre is associated with.
Universitat Autònoma de Barcelona
Universitat Autonoma de Barcelona is a major public research university in Spain with psychiatry and neuroscience programs that have contributed to psychedelic and psychopharmacology research.
View stakeholder →Hospital del Mar Medical Research Institute (IMIM), Barcelona
A Barcelona-based biomedical research institute linked to Hospital del Mar and integrated with clinical research and health innovation programs.
View stakeholder →